Skip to main content
SpringerLink
Log in

Skeletal Metabolism in Critical Illness

  • Chapter
Endocrinology of Critical Disease

Part of the book series: Contemporary Endocrinology ((COE,volume 4))

  • 113 Accesses

Abstract

Although a wealth of information has accumulated concerning physiological changes that may occur in the setting of critical illness, little has been written specifically regarding critical illness and its potential effects on the skeletal system. Not only may individual problems alter normal skeletal homeostasis, but treatment modalities used both short and long term must be considered. The skeletal system is the largest “organ” in the body, and serves a structural function and as a reservoir for calcium and other nutrients necessary for normal homeostasis and cellular action. Bone is a complex tissue and has a developmental process; it is constantly being remodeled throughout life. Its mechanical properties provide strength for skeletal support as well as protection for other organs. Changes that occur may have significance for one’s functional capacity and ability to conduct necessary activities of daily living, as well as may compromise function of internal organs. Although most changes in bone take months to years to become clinically significant, even small changes may alter the balance in individuals with pre-existing pathology or decreased reserve capacity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Delmas PD. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 1992; 13: 517–521.

    Article  Google Scholar 

  2. Uebelhart D, Gineyts E, Chapuy M-C. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8: 87–96.

    Article  PubMed  CAS  Google Scholar 

  3. Seibel MJ, Cosman F, Shen U. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8: 881–889.

    Article  PubMed  CAS  Google Scholar 

  4. Robin S, Woitge H, Hesley R. A direct enzyme linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 1643–1649.

    Article  Google Scholar 

  5. Gomez B, Ardakani S, Ju J. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase actuity in serum. Clin Chem 1995; 41: 1560–1566.

    PubMed  CAS  Google Scholar 

  6. Gomez B, Bally CA, Jenkins DK. An enzyme immunoassay for intact newly synthesized osteocalcin: a marker of bone formation (abs). International Conference on Progress in Bone and Mineral Research, Vienna, Austria, 1994.

    Google Scholar 

  7. Meunier PJ, Sellami S, Briancon D. Histological heterogeneity of apparently idiopathic osteoporosis. In: DeLuca HF, Frost HM, Jee WS, eds. Osteoporosis: Recent Advances in Pathogenesis and Treatment. University Park Press, Baltimore, 1980, p. 293.

    Google Scholar 

  8. Parfitt AM, Matthews C, Rao D. Impaired osteoblast function in metabolic bone disease. In: DeLuca HF, Frost HM, Jee WS, eds. Osteoporosis: Recent Advances in Pathogenesis and Treatment. University Park Press, Baltimore, 1980, p. 321.

    Google Scholar 

  9. Weinstein R, Bryce G, Sappington L. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984; 58: 1003–1009.

    Article  PubMed  CAS  Google Scholar 

  10. Cushing H 1982 Basophile adenomas. J Nery Ment Dis 76: 50.

    Google Scholar 

  11. Bressot C, Meunier PJ. Histomorphometric profile, pathophysiology and reversibility of corticosteroid induced osteoporosis. Metab Bone Dis Rel Res 1979; 1: 303–311.

    Article  Google Scholar 

  12. Curtiss PH, Clark WS, Herndon CH. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. JAMA 1954; 156: 467–469.

    Article  Google Scholar 

  13. Howland WJ, Pugh DG, Sprague RG. Roentgenologic changes of the skeletal system in Cushing’s syndrome. Radiology 1958; 71: 69–78.

    PubMed  Google Scholar 

  14. Sussman ML, Copelman B. The roentgenologic appearance of the bones in Cushing’s syndrome. Radiology 1942; 39: 288–292.

    Google Scholar 

  15. Maldague B, Malghem J, Nagant de Deuxchaisnes C. Radiologic aspects of glucocortinephrologist. Kidney Int 1984; 38: 193–211.

    Google Scholar 

  16. Schaadt O, Bohr H. Loss of bone mineral in axial and peripheral skeleton in aging, prednisone treatment and osteoporosis. In: Dequeker JV, Johnston CC Jr, eds. Noninvasive Bone Measurements: Methodological Problems. Oxford, IRL Press, 1982, pp. 207–214.

    Google Scholar 

  17. Sambrook PN, Eisman JA, Yates MG. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 1986; 45: 950–953.

    Article  PubMed  CAS  Google Scholar 

  18. Mitchell D, Lyles K. Glucocorticoid induced osteoporosis mechanisms for bone loss: evaluation of strategy for prevention. J Gerontol 1990; 45: M153–158.

    Article  PubMed  CAS  Google Scholar 

  19. LoCascio V, Bonucci E, Imbimbo B. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990; 8: 39–51.

    Article  PubMed  CAS  Google Scholar 

  20. Reugsegger P, Medici TC, Anliker M. Corticosteroid induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615–620.

    Article  Google Scholar 

  21. Rickers H, Deding A, Christiansen C. Corticosteroid induced osteopenia and vitamin D metabolism: effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol 1982; 16: 409–415.

    Article  CAS  Google Scholar 

  22. Dykman T, Gluck O, Murphy W. Evaluation of factors associated with glucocorticoid induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985; 23: 361–365.

    Article  Google Scholar 

  23. Curtiss PH, Clark WS, Herndon CH. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. JAMA 1954; 156: 467–469.

    Article  Google Scholar 

  24. Nagant de Deuxchaisnes C, Devogelaer JP, Esselinckx W. The effect of low dose glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry. Adv Exp Med Biol 1984; 171: 210–239.

    Google Scholar 

  25. Dempster D. Perspectives: bone histomorphometry in glucocorticoid induced osteoporosis. J Bone Miner Res 1989; 4: 137–150.

    Article  PubMed  CAS  Google Scholar 

  26. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid induced osteoporosis. Calcif Tissue Int 1983; 35: 410–417.

    Article  PubMed  CAS  Google Scholar 

  27. Meunier PJ, Dempster DW, Edouard C. Bone histomorphometry in corticosteroid induced osteoporosis and Cushing’s syndrome. Adv Exp Med Biol 1984; 171: 191–200.

    PubMed  CAS  Google Scholar 

  28. Hseuh AJ, Erickson GF. Glucocorticoid inhibition of FSH induced estrogen production in cultured rat granulosa cells. Steroids 1978; 32: 639–648.

    Article  Google Scholar 

  29. Sakakura M, Takebe K, Nakagawa S. Inhibition of leutinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975; 40: 774–779.

    Article  PubMed  CAS  Google Scholar 

  30. Macadams MR, White RH, Chipps RE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648–651.

    PubMed  CAS  Google Scholar 

  31. Raisz LG, Kream BE. Regulation of bone formation. N Engl J Med 1983; 30: 83–89.

    Article  Google Scholar 

  32. Gourmelen M, Girard F, Biuoux M. Serum somatomedin/insulin like growth factor (IGF) and IGF carrier levels in patients with Cushing’s syndrome or receiving glucocorticoid therapy. J Clin Endocrinol Metab 1982; 54: 885–892.

    Article  PubMed  CAS  Google Scholar 

  33. Reid I. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989; 30: 83–103.

    Article  CAS  Google Scholar 

  34. Hahn T, Henden B, Scharp C. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287: 900–904.

    Article  PubMed  CAS  Google Scholar 

  35. Bijlsma JW, Raymakers JA, Mosch C. Effect of oral calcium and vitamin D on glucocorticoid induced osteopenia. Clin Exp Rheumatol 1988; 6: 113–119.

    PubMed  CAS  Google Scholar 

  36. Suzuki Y, Ichikawa Y, Saito E. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32: 151–156.

    Article  PubMed  CAS  Google Scholar 

  37. Emkey R, Reading W, Procaccini P. The effect of calcitonin on bone mass in steroid induced osteoporosis. In: Abstracts of the Annual Scientific Meeting of the American College of Rheumatology, Minneapolis, 1994, p. S183.

    Google Scholar 

  38. Montemurro L, Schiraldi G, Zanni D Two years’ treatment with calcitonin nasal spray: effective protection against corticosteroid induced osteoporosis. In: Kovergaard, Christiansen C, eds. Proceedings Third International Symposium in Osteoporosis. Denmark, Glastrup Hospital, 1990.

    Google Scholar 

  39. Ringe J, Welzel D. Salmon calcitonin in the therapy of corticoid induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35–39.

    Article  PubMed  CAS  Google Scholar 

  40. Reid IR, Alexander CJ, King AR. Prevention of steroid induced osteoporosis with (3-amino-1hydroxylpropylidene) -1, 1-bisphosphonate (APD). Lancet 1988; 1: 143–146.

    PubMed  CAS  Google Scholar 

  41. Mulder H, struys A. Intermittent cyclic etidronate in the prevention of corticosteroid induced bone loss. Br J Rheumatol 1994; 33: 348–350.

    Article  PubMed  CAS  Google Scholar 

  42. Need AG. Corticosteroids and osteoporosis. Aust NZJ Med 1987; 17: 267–272.

    Article  CAS  Google Scholar 

  43. Lee YSL, Kohlmeier L, Van Vollenhoven RF. The effects of dehydroepiandrosterone (DHEA) on bone metabolism in healthy postmenopausal women. In: Abstracts of the Annual Scientific Meeting of the American College of Rheumatology, Minneapolis, 1994, p. S182.

    Google Scholar 

  44. Reid I. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989; 30: 83–103.

    Article  CAS  Google Scholar 

  45. Grecu E, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990; 46: 294–299.

    Article  PubMed  CAS  Google Scholar 

  46. Fucik RJ, Kukreja SG, Hargis GK. Effects of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 1975; 40: 152–155.

    Article  PubMed  CAS  Google Scholar 

  47. Imbimbo B, Tuzi R, Porzino F. Clinical equivalence of a new glucocorticoid deflazacort and prednisone in rheumatoid arthritis and SLE patients. In: Avioli L, Gennari C, Imbimbo B, eds. Glucocorticoid Effects and Their Biological Consequences. Plenum, New York 1983, p. 234.

    Google Scholar 

  48. Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985; 37: 592–593.

    Article  PubMed  CAS  Google Scholar 

  49. Avioli L. Heparin-induced osteoporosis: an appraisal. Adv Exp Med Biol 1975; 52: 375–387.

    Article  PubMed  CAS  Google Scholar 

  50. Rupp WM, McCarthy HB. Risk of osteoporosis in patients treated with long-term intravenous heparin therapy. Cuff Probl Surg 1982; 39: 419–422.

    CAS  Google Scholar 

  51. Griffith GC, Nichols G, Asher JD. Heparin osteoporosis JAMA 1965; 193: 85–88.

    Google Scholar 

  52. Squires JW, Pinch LW. Heparin induced spinal fractures. JAMA 1979; 241: 2417–2418.

    Article  PubMed  CAS  Google Scholar 

  53. Wise PH, Hall AS. Heparin induced osteopenia in pregnancy BMJ 1980; 281: 110–111.

    CAS  Google Scholar 

  54. Megard M, Cuche M, Grapeloux. Osteoporose de l’heparinotherapie: Analyse histomorphometrique de la biopse ossuse une observation. Nouv Presse Med 1982; 11: 261–264.

    PubMed  CAS  Google Scholar 

  55. Canalis E, McCarthy T, Centrella M. The role of skeletal growth factors in skeletal remodeling. Clin Endocrinol Metab 1989; 18: 903–919.

    Google Scholar 

  56. Schreiber AB, Kenny J, Kowalski WJ. Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition. Proc Natl Acad Sci USA 1985.

    Google Scholar 

  57. Glajchen N, Ismail F, Epstein S. The effect of chronic caffeine administration on serum markers of bone mineral metabolism and bone histomorphometry in the rat. Calcif Tissue Int 1988; 43: 277–280.

    Article  PubMed  CAS  Google Scholar 

  58. Barrett-Connor E, Chang JC, Edelstein SL. Coffee associated osteoporosis offset by daily milk consumption: The Rancho Bernardo Study. JAMA 1994; 271: 280–283.

    Article  PubMed  CAS  Google Scholar 

  59. Prince R, Monk K, Kent G. Effects of theophylline and salbutamol on phosphate and calcium metabolism in normal subjects. Miner Electrolyte Metab 1988; 14: 262–265.

    PubMed  CAS  Google Scholar 

  60. Blum JW, Fischer JA, Hunziker WH. Parathyroid hormone responses to catecholamines and to changes of extracellular calcium in cows. J Clin Invest 1978; 61: 1113–1122.

    Article  PubMed  CAS  Google Scholar 

  61. Kukreja SC, Hargis GK, Bowser EN. Role of adrenergic stimuli in parathyroid hormone secretion in man. J Clin Endocrinol Metab 1975; 40: 478–481.

    Article  PubMed  CAS  Google Scholar 

  62. Metz SA, Deftos LJ, Baylink DG, Robertson RP. Neuroendocrine modulation of calcitonin and parathyroid hormone in man. J Clin Endocrinol Metab 1978; 47: 151–159.

    Article  PubMed  CAS  Google Scholar 

  63. Brown EM, Gardner DG, Windeck RA. B-Adrenergically stimulated adenosine 3’, 5’-monophosphate accumulation in and parathyroid hormone release from dispersed human parathyroid cells. J Clin Endocrinol Metab 1979; 48: 618–626.

    Article  PubMed  CAS  Google Scholar 

  64. Mulder H, Struys A. Intermittent cyclic etidronate in the prevention of corticosteroid induced bone loss. Br J Rheumatol 1994; 33: 348–350.

    Article  PubMed  CAS  Google Scholar 

  65. Rodbro P, Christiansen C, Lund M. Development of anticonvulsant osteomalacia in epileptic patients on phenytoin treatment. Acta Neurol Scand 1974; 50: 527–532.

    Article  PubMed  CAS  Google Scholar 

  66. Tolman KG, Jubiz W, Sannella J. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45–51.

    PubMed  CAS  Google Scholar 

  67. Jubiz W, Meikle AW, Levinson RA. Effect of diphenylhydantoin on the metabolism of dexamethasone: mechanisms of the abnormal dexamethasone suppression in humans. N Engl J Med 1970; 283: 11–14.

    Article  PubMed  CAS  Google Scholar 

  68. Hahn T, Birge S, Scharp C. Phenobarbital induced alterations in vitamin D metabolism J Clin Invest 1972; 51: 741–748.

    CAS  Google Scholar 

  69. Koch HV, Kraft D, Von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972; 13: 829–841.

    Article  PubMed  CAS  Google Scholar 

  70. Hahn T, scharp C, Richardson C. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978; 62: 496–414.

    Article  Google Scholar 

  71. Dietrich J, Duffield R. Effects of diphenylhydantoin on synthesis of collagen and noncollagen protein in tissue culture. Endocrinology 1980; 106: 606–610.

    Article  PubMed  CAS  Google Scholar 

  72. Krolner B, Jorgensen JV, Nielsen SP. Spinal bone mineral content in myxedema and thyrotoxicosis: effects of thyroid hormones and antithyroid treatments. Clin Endocrinol 1983; 18: 439–446.

    Article  CAS  Google Scholar 

  73. Meunier P, Bianchi G, Edouard C. Bony manifestation of thyrotoxicosis. Orthop Clin North Am 1972; 3: 745–774.

    Google Scholar 

  74. Toft A. Thyroxine therapy. N Engl J Med 1994; 331: 174–181.

    Article  PubMed  CAS  Google Scholar 

  75. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19: 35–63.

    PubMed  CAS  Google Scholar 

  76. Mosekilde L, Melsen F, Bagger JP. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium phosphorus metabolism. Acta Endocrinol 1977; 85: 515–525.

    PubMed  CAS  Google Scholar 

  77. Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 1985; 6: 421–428.

    Article  PubMed  CAS  Google Scholar 

  78. Burman KD, Monchik JM, Earll JM. Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 1976; 84: 668–671.

    PubMed  CAS  Google Scholar 

  79. Manicourt D, Demeester-Mirkine N, Brauman H. Disturbed mineral metabolism in hyperthyroidism: good correlation with triiodothyronine. Clin Endocrinol 1979; 101: 407–412.

    Article  Google Scholar 

  80. Stall G, Harris S, Sokoll L. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990; 113: 265–269.

    PubMed  CAS  Google Scholar 

  81. Paul T, Kerrigan J, Kelly AM. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137–3141.

    Article  PubMed  CAS  Google Scholar 

  82. Ross D, Neer R, Ridgway EC. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary thyroid axis with L-thyroxine. Am J Med 1987; 82: 1167–1170.

    Article  PubMed  CAS  Google Scholar 

  83. Adlin EM, Maurer AM, Marks AD. Bone mineral density in postmenopausal women treated with thyroxine. Am J Med 1991; 90: 360–366.

    Article  PubMed  CAS  Google Scholar 

  84. Baylink D, Stauffer M, Wergedal J, Rich C. Formation mineralization and resorption of bone in vitamin-D deficient rats. J Clin Invest 1970; 49: 1122–1134.

    Article  PubMed  CAS  Google Scholar 

  85. Barnes MJ, Constable BJ, Morton LF, Kodicek E. Bone collagen metabolism in vitamin-D deficiency. Biochem J 1973; 132: 113–115.

    PubMed  CAS  Google Scholar 

  86. Frame B, Parfitt AM. Osteomalacia: current concepts. Ann Intern Med 1978; 89: 966–982.

    PubMed  CAS  Google Scholar 

  87. Kanis JA. Pathophysiology and Treatment of Paget’s Disease of Bone. Carolina Academic Press, London.

    Google Scholar 

  88. Dove J. Complete fractures of the femur in Paget’s disease of bone. J Bone Joint Surg 1980; 62B: 12–17.

    Google Scholar 

  89. Boonekamp PM, van der Wee Pals LJA, van Wij-van Lennep MLL. Two modes of action of biophosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1: 27–39.

    PubMed  CAS  Google Scholar 

  90. Sins E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab 1996; 81: 961–967.

    Article  Google Scholar 

  91. Chesnut CH III. Review of calcitonin-present: current status of calcitonin as a therapeutic agent. Bone Miner 1992; 16: 211–212.

    Article  PubMed  Google Scholar 

  92. Devogelaer JP. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int 1994; 55: 71–73.

    Article  PubMed  CAS  Google Scholar 

  93. Luboshitzky R, Bar-Shalom R. Calcitonin nasal spray for Paget’s disease of the bone. Harefuah 1995; 128: 358–362.

    PubMed  CAS  Google Scholar 

  94. Wimalawansa SJ. Dramatic response to plicamycin in a patient with severe Paget’s disease refractory to calcitonin and pamidronate. Semin Arthritis Rheum 1994; 23: 267.

    Article  PubMed  CAS  Google Scholar 

  95. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 1991; 114: 593–597.

    Google Scholar 

  96. Parfitt AM. Equilibrium and disequilibrium hypercalcemia: new light on an old concept. Metab Bone Dis Relat Res 1979; 1: 279–293.

    Article  Google Scholar 

  97. Kaiser W, Biesenbach G, Kramar R. Calcium free hemodialysis: an effective therapy in hypercalcemic crisis-report of 4 cases. Intens Care Med 1989; 15: 471–474.

    Article  CAS  Google Scholar 

  98. Binshock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 1980; 93: 269–272.

    Google Scholar 

  99. Ljunghall S, Rastad J, Akerstrom G. Comparative effects of calcitonin and clodronate in hypercalcemia. Bone 1987; 8: S79 - S83.

    Article  PubMed  Google Scholar 

  100. Mundy GR, Wilkinson R, Health DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983; 74: 421–432.

    Article  PubMed  CAS  Google Scholar 

  101. Warrell RP, Israel R, Frisone M. Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized, double-blind comparison to calcitonin. Ann Intern Med 1988; 108: 669–674.

    PubMed  Google Scholar 

  102. Mallette LE, Bilezikian JP, Heath DA. Primary hyperparathyroidism: Clinical and biochemical features. Medicine 1974; 53: 127–146.

    Article  PubMed  CAS  Google Scholar 

  103. NIH. NIH Consensus Development Conference Statement: Diagnosis and management of asymptomatic primary hyperparathyroidism. Ann Int Med 1991; 114: 593–597.

    Google Scholar 

  104. Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982; 306: 1136–1140.

    Article  PubMed  CAS  Google Scholar 

  105. Galasko CSB. Skeletal metastases. Clin Orthop 1990, (September):18–30.

    Google Scholar 

  106. Poste G. Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rev 1986; 70: 183–199.

    CAS  Google Scholar 

  107. Garrett RI, Durie BGM, Nedwin GE. Production of the bone resorbing cytokine lymphotoxin by cultured human myeloma cells. N Engl J Med 1987; 317: 526–532.

    Article  PubMed  CAS  Google Scholar 

  108. Cozzolino F, Torcia M, Aldinucci D. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 387–390.

    Google Scholar 

  109. Bataille R, Jourdan M, Zhang Xue-Guang. Serum levels of interleukin-6, a potent myeloma cell growth factor as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008–2011.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Steven R. Gambert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Peterson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Endocrinology and Metabolism, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC, USA

    K. Patrick Ober MD

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gambert, S.R., Peterson, S.J. (1997). Skeletal Metabolism in Critical Illness. In: Ober, K.P. (eds) Endocrinology of Critical Disease. Contemporary Endocrinology, vol 4. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4757-2584-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-2584-1_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-032-8

  • Online ISBN: 978-1-4757-2584-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation